Bo Ma

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

David Planchard, Tae Min Kim, Julien Mazières et al. · The Lancet Oncology · 2016 · 439 citations · Full text

Oncology, Non-small-cell Lung Cancer, Pathology +7

An EMT‐related gene signature for the prognosis of human bladder cancer

Rui Cao, Lushun Yuan, Bo Ma et al. · Journal of Cellular and Molecular Medicine · 2019 · 204 citations · Full text

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Katherine L. Nathanson, Anne‐Marie Martin, Bradley Wubbenhorst et al. · Clinical Cancer Research · 2013 · 183 citations · Full text

Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi

Bo Ma, Bea Christen, Danny T. M. Leung et al. · Journal of Clinical Microbiology · 1992 · 154 citations · Full text

Parasitic Disease, Allergy, Autoimmune Disease +15

Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)

Rui Cao, Lushun Yuan, Bo Ma et al. · Cancer Immunology Immunotherapy · 2020 · 121 citations · Full text

Immunotherapy Response, Urology, Tumor Immunology +9